tbuckley/cabot-search huggingface dataset:
Former banker who hiked price of drug refuses to speak at congressional hearing
Authors: Owen Dyer
Journal: BMJ (2016)

<h3>Abstract</h3> SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 mutations found in the B.1.1.7 Spike protein. The vaccine sera exhibited a broad range of neutralizing titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralization was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 outof 29), but not in neutralizing mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralizing activity by vaccine-elicited antibodies over that conferred by the B.1.1.7 mutations alone. Further work is needed to establish the impact of these observations on protective vaccine efficacy in the context of the evolving B.1.1.7 lineage.
Endoscopic removal of benign stenotic formations of larynx, trachea and bronchi
Authors: Shuhrat Hudaybergenov, Georgy Pahomov, Rustem Hayaliev, Otabek Eshonhodjaev, Jahongir Biybalaev
Journal: European Respiratory Journal (2013)

Introduction. Stenotic formations of the larynx, trachea and bronchi still remain as an actual problem of thoracic surgery and otorhinolaryngology. Removal of the formations can be done in an open way, by opening the lumen with a subsequent restoration of intactness and also by endoscopic methods.

Material and Methods: The results of treatment of 48 patients with stenotic benign formations of larynx, trachea and bronchi have been analysed. Modern methods of diagnostics including TBFS with biopsy and MSCT with 3D-reconstruction and virtual bronchoscopy have been used. The treatment included: a laser photodestruction, an endoscopic removal of benign stenotic formations of larynx, trachea and bronchi using electrocoagulation loops performed via an under-narcosis rigid bronchoscopy with the respiratory tube of Storz bronchoscopes, and also through the instrument channels of the Olympus and Pentax bronchoscopes under local anesthesia and intravenous sedation.

Results and discussion: After emergency or routine endoscopic interventions with the restoration of the airway, status of patients has significantly improved, dyspnoea has disappeared completely, phonation has been restored, symptoms of bronchitis resulting from disruptions of expectoration of the mucosal or mucosal-purulent sputum have stopped. In the case of restenosis in the place of removed granulomas in 9 patients endotracheal stents of different configuration and model have been used.

Conclusion: Thus, the endoscopic removal of benign exophytic formations of larynx, trachea and bronchi, in the absence of invasion to the wall of the organ without signs of endophytic growth, is an effective and independent method of a treatment.
Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking
Authors: James R. Byrnes, Cédric Duval, Yiming Wang, Caroline E. Hansen, Byungwook Ahn, Micah J. Mooberry, Martha A. Clark, Jill M. Johnsen, Susan T. Lord, Wilbur A. Lam, Joost C. M. Meijers, Heyu Ni, Robert A. S. Ariëns, Alisa S. Wolberg
Journal: Blood (2015)
Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
Authors: D Decaudin, J Bosq, G Tertian, G Nedellec, A Bennaceur, A M Venuat, C Bayle, P Carde, B Bendahmane, M Hayat, J N Munck
Journal: Journal of Clinical Oncology (1998)

PURPOSE The aim of this phase II trial was to assess the efficacy of fludarabine monophosphate in untreated and pretreated mantle-cell lymphomas (MCL). PATIENTS AND METHODS Fifteen patients with MCL were included in the study. In two cases, fludarabine was the first-line therapy, the second in four cases, the third in five cases, and the fourth in four cases. The diagnosis of MCL was based on the criteria of the European Lymphoma Task Force (ELTF), with morphologic, immunologic, and cytogenetic data. Patients were treated with intravenous fludarabine 25 mg/m2/d for 5 days every 4 weeks. RESULTS Toxicity of fludarabine was mild: World Health Organization (WHO) grade 3 and 4 granulocytopenia occurred in 15 of 56 assessable cycles (cy) (27%), there was no grade 3 or 4 thrombocytopenia, one grade 3 bacterial lung infection, and no treatment-related death. There were five partial responses (33%) but no complete response. The duration of these responses was short and ranged from 4 to 8 months. CONCLUSION These results suggest that fludarabine can be moderately effective in the treatment of MCL. Fludarabine appears to be far less effective than in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL). Therefore, fludarabine should be evaluated in association with other chemotherapeutic agents in MCL.
Percutaneous radiofrequency ablation of stage IA non-small cell lung cancer: A prospective multicenter clinical trial
Authors: R. A. Lencioni, L. Crocetti, R. Cioni, M. Ambrogi, A. Mussi, C. A. Angeletti, A. Wallace, R. Suh, C. Bartolozzi
Journal: Journal of Clinical Oncology (2004)

7175 Background: This study is designed to determine feasibility, safety, and effectiveness of percutaneous computed tomography (CT)-guided radiofrequency ablation (RFA) of stage IA non-small cell lung cancer (NSCLC). Methods: Fourteen patients (12 males and 2 females; age range, 50–74 years; mean, 66.1 years ± 6.9; median, 67.5 years) with stage IA, biopsy-proven NSCLC were enrolled in a prospective, multicenter clinical trial. Lesion diameter ranged 1.0–3.0 cm (mean, 2.2 cm ± 0.7). All patients were considered unfit for surgery and radical radiotherapy. CT-guided RFA was performed under conscious sedation by using a 150-W generator and expandable multi-array needles (RITA Medical Systems, Mountain View, CA). Follow-up period ranged 1–14.5 months (mean, 8.2 months ± 4.9) and included CT examinations performed 1 and 3 months after the procedure and at 3-month intervals thereafter. Results: RFA was technically feasible in all 14 patients. CT obtained 1 month after RFA showed a round, ground-glass density area encompassing the treated lesion in all cases. Nine (82%) of 11 patients who were followed up for at least 6 months after RFA showed progressive shrinkage of the treated lesion on CT scans, with no signs of local recurrence. Complete ablation of treated tumors was confirmed by the absence of tumor re-growth over a follow-up period of 1 year or more in 7 patients. Two patients with local tumor progression on follow-up CT scans required repeated RFA. Major complications consisted of pneumothorax (n=3) and pleural effusion (n=1) requiring drainage. Pulmonary function tests and quality of life questionnaires did not show any significant decline with respect to baseline. At the time of the analysis, 12 patients were alive, and 2 patients were dead. Preliminary survival analysis showed a 1-year overall survival rate of 81%, and a 1-year cause-specific survival rate of 100%. Conclusions: Percutaneous RFA yields high local tumor control rates in patients with stage IA NSCLC, and is associated with acceptable morbidity. RFA might prove a viable alternate or complementary treatment method for stage IA NSCLC in patients without surgical prospects. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration RITA Medical Systems
Survivin: A potential predictive and prognostic marker in multimodal rectal cancer therapy.
Authors: T. Sprenger, F. Rodel, H. Rothe, T. Beissbarth, L. Conradi, B. M. Ghadimi, H. Becker, C. Rödel, T. Liersch
Journal: Journal of Clinical Oncology (2010)

e14115 Background: Preoperative radiochemotherapy (RCT) is currently recommended in locally advanced rectal cancer with enhanced local control, higher sphincter preservation and decreased toxicity rates. Reliable predictive markers for an individualization of multimodal treatment are still lacking. We evaluated the intratumoral expression of survivin, an inhibitor of apoptosis, and its association with tumor regression parameters and prognosis in rectal cancer patients. Methods: 63 patients with stage II/III rectal cancers received multimodal treatment with curative surgery. 38 patients received preoperative RCT, 25 patients underwent primary surgery followed by adjuvant RCT. Nuclear and cytoplasmatic survivin expression were determined by immunhistochemistry in tumor biopsies and corresponding surgical specimens and were correlated with clinicopathologic parameters and survival. Results: In tumor biopsies, a high cytoplasmatic survivin expression correlated with advanced initial tumor stage (cT), whereas low survivin expression was associated with higher histomorphologic tumor regression after preoperative RCT. High survivin levels in surgical specimens were associated with advanced tumor stage in patients undergoing preoperative RCT, but not in patients after primary surgery. Preoperative RCT led to a significant down-regulation of intratumoral nuclear and cytoplasmatic survivin expression. Survivin down-regulation significantly correlated with RCT-induced reduction of tumor stage. However, comparing tumor biopsy and surgical specimen a deficient down-regulation of survivin was associated with an increased incidence of local recurrence. Conclusions: Our findings suggest that cytoplasmatic survivin expression in rectal cancer might be useful for response prediction to preoperative RCT and as a prognostic marker within multimodal treatment conceptions. Further investigations in a larger number of patients have to be initiated to validate these results. No significant financial relationships to disclose.
원저 : 만성 C 형간염바이러스 감염에서 Core 단백과 NS3 단백에 대한 말초혈액단핵세포의 면역반응
Authors: 정숙향(Sook Hyang Jeong), 양민진(Min Jin Yang), 이기호(Kee Ho Lee), 윤연숙(Yeon Sook Yun), 최요한(Yo Han Choi)
Journal: Clinical and Molecular Hepatology (2001)

Badqground/Aims' The aims of our study are to assess the frequency of peripheral blood mononuclear cell (PBMC) proliferation and cytokine profiles to hepatitis C virus (HCV) core protein and NS3 protein to search the potential immunosuppressive effect of HCV core in chronically HCV-infected patients. Subjects and Methods' Thirty two anti-HCV-positive patients with chronic liver diseases, eight HBsAg-positive patients with chronic liver diseases, and six healthy adults were the subjects of our study. Using recombinant HCV core and NS3, proliferative response of PBMC and cytokine production were determined. Results' Fifty nine percent and thirteen percent of patients with HCV-related chronic liver diseases showed positive PBMC proliferation to HCV core and NS3, respectively. Thirty four percent and fifty nine percent of patients with HCV-related chronic liver diseases showed significant production of interferon-gamma to HCV core and NS3, respectively. IL-4 production was negligible. When the PBMC were treated with HCV core and NS3 concurrently, or HCV core and phytohemagglutinin conaxvently, the stimulation indices were significantly decreased compared to those treated either with NS3 or PHA without core. Conclusions' Although about two thirds of chronically HCV-infected patients with liver diseases showed the PBMC proliferation and Th 1 type cytokine profile, they could not eradicate the viral infection. This ineffective immune response seems to play a role in the pathogenesis of chronic inflammatory liver disease resulting in liver cirrhosis and hepatocellular carcinoma. HCV core showed a potential immunosuppressive effect, which has important meaning for the mechanism of HCV persistence. (Korean J Hepatol 2001;7:292-298)
Clinical Presentation in Brca1/2 Mutation Carriers: A Single-Institution Experience
Authors: A. Fontana, P. Aretini, I. Ferrarini, E. Bona, I. Stasi, E. Landucci, G. Allegrini, M. Roncella, M.A. Caligo, A. Falcone
Journal: Annals of Oncology (2012)
Characterization of Murine Rauscher Leukemia Virus Propagated in Human Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Ablashi, D. V., Turner, W., Armstrong, G. R., Bass, L. R.
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Characterization of Murine Rauscher Leukemia Virus Propagated in Human Cells Get access D. V. Ablashi, D. V. Ablashi Viral Leukemia and Lymphoma Branch and Viral Biology Branch, National Cancer Institute,6Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar W. Turner, W. Turner Viral Leukemia and Lymphoma Branch and Viral Biology Branch, National Cancer Institute,6Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar G. R. Armstrong, G. R. Armstrong Viral Leukemia and Lymphoma Branch and Viral Biology Branch, National Cancer Institute,6Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar L. R. Bass L. R. Bass Viral Leukemia and Lymphoma Branch and Viral Biology Branch, National Cancer Institute,6Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 3, March 1972, Pages 615–621, https://doi.org/10.1093/jnci/48.3.615 Published: 01 March 1972 Article history Received: 20 September 1971 Accepted: 17 November 1971 Published: 01 March 1972
Phase I dose-escalating study of bi-weekly pemetrexed (MTA) with fixed dose rate gemcitabine (gem) in patients with advanced cancer
Authors: A. L. Chen, T. Ryan, F. Muggia, A. Chachoua, J. Escalon, S. Moore, F. Haniff, B. Levinson, S. Nicol, H. Hochster
Journal: Journal of Clinical Oncology (2006)

2049 Background: Fixed dose rate (FDR) gem may optimize the documented benefit of gem in pancreatic, NSCL, head and neck, and breast cancers. Preclinical data of the combination of MTA and gem indicate synergy. We studied a bi-weekly combination of MTA and FDR gem to improve tolerance over the previous “Day 1, 8” regimen. Methods: MTA followed by FDR gem infusion was given every 14 days in a dose-escalation design below. Dose-limiting toxicities (DLT) is defined as: grade 4 neutropenia ≥ 5 days, febrile neutropenia, grade 4 thrombocytopenia, or grade 3–4 non-hematological toxicities in 1st cycle. 27 patients were enrolled with median age 59 (range 41–82), males/females 18/9, and ECOG PS 0/1 (5/22). All received Vitamin B12 (1 mg IM prior to study &amp; q9 weeks) and folic acid (350–1000 mcg po qd) supplementation 1–2 weeks prior and during study plus dexamethasone 4 mg po BID day before, of, and after chemotherapy. Results: Dose level 7 has been reached and is being expanded with DLT in 1 patient. Toxicities per patient during all cycles include grade 3–4 neutropenia (8/27 patients), grade 3 anemia (3), brief febrile neutropenia (6), grade 3 rash (1 patient), grade 3 low back pain (1), grade 3 renal failure (1), grade 5 perforated duodenal stent (1). In 19 patients evaluable for response, there were 11 stable disease and 8 progression of disease. Conclusion: Recommended phase II dose for bi-weekly MTA with FDR gem is likely to be 800 mg/m 2 and 1,200 mg/m 2 × 120 minutes. This regimen allows full doses and dose intensity of both drugs to be administered on a simple schedule with excellent tolerance. A phase II study in biliary cancer is planned. This study is supported in part by Eli Lilly. a This toxicity was at baseline, therefore not drug related. b, c These toxicities were in one patient and were not drug related, rather related to the individual patient’s status going into therapy. [Table: see text] [Table: see text]
Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom
Journal: BMJ (2004)

To assess the feasibility of introducing into the UK's NHS a national screening programme for colorectal cancer based on faecal occult blood testing.Demonstration pilot.Two English health authorities and three Scottish health boards.People aged 50-69 years.478,250 residents of the pilot areas were invited to take part in the screening programme. Uptake (the proportion in whom a final faecal occult blood test result was available) was 56.8% (n = 271,646). The overall rate of a positive test result was 1.9% and the rate for detecting cancer was 1.62 per 1000 people screened. Both these values were higher in Scotland than in England, higher in men than in women, and increased with age. The positive predictive value was 10.9% for cancer and 35.0% for adenoma. 552 cancers were detected by screening; 92 (16.6%) were polyp cancers. 48% of all screen detected cancers were Dukes's stage A, and 1% had metastasised at the time of diagnosis.Screening for colorectal cancer by testing for faecal occult blood is feasible within the context of the United Kingdom's NHS. Screening should lead to a reduction in deaths from colorectal cancer in the population offered screening.
Congenital heart disease: a deductive approach to its diagnosis. (3rd edition): By B W Fink. (Pp 226; 15.) St Louis: Mosby Year Books, 1991. ISBN 0-8151-3387-1
Authors: C. Saldanha
Journal: Cardiovascular Research (1995)

Congenital heart disease: a deductive approach to its diagnosis. (3rd edition): By B W Fink. (Pp 226; £15.) St Louis: Mosby Year Books, 1991. ISBN 0-8151-3387-1 Get access Congenital Heart Disease: a Deductive Approach to its Diagnosis. (3rd edition.) By Fink B W. (Pp 226; £15.) St Louis: Mosby Year Books, 1991). ISBN 0-8151-3387-1. Clyde Saldanha Clyde Saldanha London, UK Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 29, Issue 2, February 1995, Page 295, https://doi.org/10.1016/S0008-6363(95)90023-3 Published: 01 February 1995
Efficacy and safety of oral bosentan in patients with Down's syndrome and pulmonary arterial hypertension due to congenital heart disease
Authors: Michele D'Alto, Emanuele Romeo, Paola Argiento, Anna Correra, Berardo Sarubbi, Maria Pignatiello, Antonietta Caronna, Carmine Dario Vizza, Raffaele Calabrò, Maria Giovanna Russo
Journal: European Respiratory Journal (2012)

Aim. To evaluate the long-term effects of oral bosentan in adult patients with pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD) with and without Down's syndrome.

Methods. WHO functional class, 6-minute walk test (6MWT) and hemodynamics were assessed at baseline and after 12 months of bosentan therapy in CHD-PAH patients with and without Down's syndrome.

Results. Seventy-four consecutive patients were enrolled: 18 with and 56 without Down's syndrome. After 12 months of bosentan therapy, both groups showed an improvement in WHO functional class, 6-minute walk distance and hemodynamics.

View this table:

Clinical and haemodynamic variables before and after oral bosentan treatment in patients with and without Down's syndrome





No differences in the efficacy of therapy were observed between the two groups.

Conclusions. Bosentan was safe and well tolerated in adult patients with CHD-related PAH with and without Down's syndrome during 12 months of treatment. Clinical status, exercise tolerance, and pulmonary hemodynamics improved, regardless of the presence of Down's syndrome.
Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation treatment in early stage high-risk and advanced endometrial cancer
Authors: H. Kim, J. Kim, H. Chung, N. Park, Y. Song, S. Kang, H. Lee
Journal: Journal of Clinical Oncology (2008)

16591 Background: To compare response, toxicity and survival between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation treatment in early stage high-risk and advanced endometrial cancer. Methods: Among 365 patients diagnosed as endometrial cancer, clinical data of 33 patients treated with paclitaxel/carboplatin (n=21, group I) or doxorubicin/cisplatin (n=12, group II) for concurrent chemoradiation treatment after staging laparotomy were reviewed between March 1999 and October 2007. 135 mg/m2 (24-hour infusion) or 175 mg/m2 (3-hour infusion) of paclitaxel and AUC 4.5 or 5 of carboplatin every 3 weeks were administered to patients in group I while the others received 50 mg/m2 of doxorubicin and 60 mg/m2 of cisplatin every 3 weeks. Response by CT and hematological toxicity were evaluated using Chi-square or Fisher’s exact test in both groups. Progression-free survival (PFS) and overall survival (OS) between two groups were compared by Kaplan-Meier analysis. Results: The median age of all patients was 53 years (range, 36–70 years). Eighty cycles were administered with median cycles of 3 in group I (range, 2- 9) whereas 75 cycles with median cycles of 6 in group II (range, 3–9) (P=.010). According to the FIGO criteria, 7 (21.2%) patients were in stage IC, 2 (6.0%) in stage II, 19 (57.5%) in stage III and 5 (15.2%) in stage IV. Overall response rates were 90.5% (19/21) and 83.3% (10/12) in groups I and II, respectively (P=.610). Grade 3 or 4 anemia and thrombocytopenia were less frequent in group I than group II (5.0% versus 17.3% in cycles for anemia, P=.047; 4.8% versus 33.3% in patients and 0.0% versus 8.0% in cycles for thrombocytopenia, P = .047 and P = .012, respectively). PFS and OS were higher in group I than group II although there was no significant difference (median PFS, 35 vs. 7 months, P=.1739; median OS, 76 vs. 39 months, P = .3162). Conclusions: Paclitaxel/carboplatin may have comparable efficacy and lower toxicity with lesser administration than doxorubicin/cisplatin for concurrent chemoradiation treatment in early stage high-risk and advanced endometrial cancer. No significant financial relationships to disclose.